Last reviewed · How we verify
BMS-986249
At a glance
| Generic name | BMS-986249 |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS-986249 CI brief — competitive landscape report
- BMS-986249 updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI